Available study revealed non-small cell lung cancer (NSCLC) patients faced a risk of disease flare after cessation of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment. There was no data concerning the prognostic value of disease flare. This study aimed to investigate the prevalence of disease flare in a Chinese cohort, and analyzed its prediction to survival. A cohort of 227 NSCLC patients with acquired resistance to EGFR TKI was retrospectively analyzed. Prevalence and clinical features of disease flare after TKI cessation were reviewed. Survival data were analyzed between patients with flare and those without flare. EGFR gene mutations in tumors were detected. Twenty of 227 (8.8 %) patients were determined with disease flare after TKI cessation. The median interval from TKI cessation to disease flare was 7 days (range 3-18). Forty percent of patients complained of deteriorated dyspnea attributable to malignant effusion. Thirty percent of patients had progressive lesions in the brain. After TKI cessation 35 % of flare patients died before challenge of subsequent treatment. No response was observed in 30 % of flare patients undergoing subsequent chemotherapy. When compared with the non-flare group, patients with disease flare demonstrated comparable progression-free survival (10.1 vs. 9.9 months; P = 0.973), shorter post-TKI survival (4.1 vs. 6.1 months; P < 0.001), and a significantly poor overall survival (16.6 vs. 21.6 months; P = 0.002). Disease flare after cessation of EGFR TKI occurred in Chinese NSCLC population and predicted a poor survival.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12253-013-9651-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Burden of mild and moderate atopic dermatitis in adults: results from a real-world study in the United States.
Arch Dermatol Res
March 2025
HTA, Value and Evidence, Pfizer Inc, Groton, CT, USA.
Few studies explore the burden of mild-to-moderate atopic dermatitis (AD). We aimed to investigate disease burden in mild-to-moderate AD using real-world data from adults with AD and their physicians in the United States. Data were drawn from the Adelphi Real World AD Disease Specific Programme™, a cross-sectional survey of physicians and their patients with AD in real-world clinical practice in the US from November 2014 to February 2015.
View Article and Find Full Text PDFPrediction of Flares in Systemic Lupus Erythematosus During Post-Remission Follow-up.
J Inflamm Res
March 2025
Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, People's Republic of China.
Purpose: Patients at high risk of SLE flares benefit from being identified before flares; this can be done by predictors of flares. This study aimed to explore the predictive factors and model of SLE flares after remission, providing basis for clinical decision-making.
Patients And Methods: SLE patients recruited at the Peking Union Medical College Hospital (PUMCH), were all registered in the Chinese SLE treatment and research (CSTAR) registry cohort and had experienced at least one remission before December 31, 2020.
A Prospective Observational Study to Evaluate the Actual Use of 1% Pimecrolimus in Chinese Patients with Mild-to-Moderate Atopic Dermatitis Affecting Sensitive Skin Areas.
Pragmat Obs Res
March 2025
Department of Dermatology, Capital Institute of Pediatrics, Beijing, People's Republic of China.
Introduction: Atopic dermatitis (AD) is a common inflammatory skin disorder that affects both children and adults, characterized by pruritus and scaly, dry eczematous lesions. This study aimed to gather knowledge on the actual use and effectiveness of Pimecrolimus (PIM) in Chinese patients with mild-to-moderate AD affecting sensitive skin areas in routine clinical practice.
Methods: This multicentre and non-interventional study included 130 subjects from China, divided into two age groups (2-12 years and ≥12 years).
Disease activity during pregnancy in patients with rheumatoid arthritis or spondyloarthritis: results from the multicentre prospective GR2 study.
BMC Rheumatol
March 2025
Rheumatology Department, Hôpital Cochin, AP-HP, Paris, France.
Background: Pregnancy may have a beneficial effect on disease activity in rheumatoid arthritis (RA) but the evidence is more conflicting in spondyloarthritis (SpA). The aim of this study was to analyse disease activity and relapse during pregnancy in women with RA and SpA.
Methods: Consecutive pregnant women with RA or SpA were enrolled in this French multicentre observational cohort from 2014 to 2022.
Transformative Results in Giant Pyoderma Gangrenosum with Dexamethasone-cyclophosphamide Pulse.
Ann Afr Med
March 2025
Department of Dermatology, Dr. D. Y. Patil Medical College and Hospital, Pune, Maharashtra, India.
Pyoderma gangrenosum (PG) is a cutaneous ulcerative condition that can present in various forms, including ulcerative, bullous, pustular, vegetative, and peristomal. It often occurs and recurs in areas subjected to trauma due to the pathergy phenomenon, where irritation or injury triggers flare-ups. The condition typically begins as a painful erythematous lesion that rapidly progresses to a necrotic or blistering ulcer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!